Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Rhea-AI Summary

Taysha Gene Therapies has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for TSHA-102 in Rett syndrome. This designation allows for increased dialogue with the FDA to support expedited development and review of the therapy. The RMAT designation was granted based on the safety and efficacy data from the first three patients dosed with TSHA-102 in clinical trials.

Positive

• RMAT designation granted by the FDA for TSHA-102 in Rett syndrome, indicating recognition of the therapy's potential to address unmet medical needs.

• Potential for expedited development and review of TSHA-102 due to RMAT designation, enabling increased dialogue with the FDA to support the therapy's advancement.

• Positive review of safety and efficacy data from the first three patients dosed with TSHA-102 led to the RMAT designation, reinforcing the therapy's potential to bring meaningful change to patients with Rett syndrome.

Negative

• None.

Insights

Medical Research Analyst

The RMAT designation is a pivotal step for Taysha Gene Therapies as it often indicates a treatment's significant potential to fill an unmet medical need. Given the rarity and complexity of Rett syndrome, such designations are essential for accelerating the development process, which can be arduous and time-consuming. From a scientific standpoint, the ability to expedite dialogue with the FDA may help to address any clinical and regulatory hurdles more efficiently, providing a clear pathway for TSHA-102's development and potentially shortening the time to market. Although the designation is based on early clinical data, which is promising, investors should note the inherent risks of drug development. The final efficacy and safety profile of TSHA-102 will only be confirmed through comprehensive Phase 3 trials and subsequent FDA approvals. Nonetheless, this news reflects positively on Taysha's research capabilities and its strategic regulatory approach to drug development.

Biotech Financial Analyst

The RMAT designation for TSHA-102 may lead to a positive sentiment among investors, as it demonstrates regulatory confidence in the therapy's potential and can streamline its path to market. Historically, such designations have been viewed favorably by the market and can often lead to an uptick in a company's stock valuation due to the perceived reduction in regulatory risk. However, it is important to exercise caution; the clinical-stage nature of Taysha Gene Therapies means that it is still subject to the high volatility that is typical within the biotech sector. Investors should consider the company's burn rate, cash reserves and the timeline for further clinical trial results when assessing the potential impact on the stock's performance. Any delays or negative outcomes in future trials could significantly affect the company's valuation.

RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL Phase 1/2 trials (adolescent/adult and pediatric)

RMAT designation enables increased dialogue with the FDA to support the potential expedited development and review of TSHA-102 in clinical evaluation for Rett syndrome

DALLAS, May 02, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced the United States Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to TSHA-102, a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome. RMAT designation was granted following the FDA’s review of clinical data supporting the potential of TSHA-102 to address the unmet medical need for patients with Rett syndrome.

RMAT designation was designed to expedite the development and review of regenerative medicine therapies. A regenerative medicine therapy is eligible for RMAT designation if it is intended to treat, modify, reverse or cure a serious condition, and preliminary clinical evidence indicates the therapy has the potential to address unmet medical needs for such condition. Sponsor companies receiving RMAT designation can benefit from increased interactions with the FDA involving senior managers, with the goal of expediting drug development. RMAT designation follows the FDA’s review of available safety and efficacy data from the first three patients with Rett syndrome dosed with the low dose of TSHA-102 (5.7x10¹⁴ total vg) across the REVEAL Phase 1/2 adolescent and adult trial and the REVEAL Phase 1/2 pediatric trial.

“We believe receiving RMAT designation reinforces the high unmet medical need in Rett syndrome and the therapeutic potential of TSHA-102 to change the treatment paradigm,” said Sukumar Nagendran, M.D., President and Head of R&D of Taysha. “Importantly, RMAT designation was granted following the FDA’s review of safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both of our REVEAL Phase 1/2 trials. We believe this important recognition from the FDA further supports the potential of our gene therapy candidate to bring meaningful change to patients and families living with Rett syndrome.”

Rumana Haque-Ahmed, Chief Regulatory Officer of Taysha, added, “We remain focused on advancing the development TSHA-102 to bring a potentially disease-modifying therapy being evaluated to address the genetic root cause of Rett syndrome to all patients and families living with this devastating disease. Receiving RMAT designation helps facilitate this goal by enabling increased dialogue with the FDA to expedite our development plan for TSHA-102. We look forward to working closely with the FDA and other regulatory agencies as we continue to advance our TSHA-102 program.”

TSHA-102 is being evaluated in the REVEAL Phase 1/2 adolescent and adult trial taking place in Canada and the U.S., and in the REVEAL Phase 1/2 pediatric trial taking place in the U.S. and cleared in the U.K.

About TSHA-102
TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome. Designed as a one-time treatment, TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of MECP2 to cells in the CNS. TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression. TSHA-102 has received Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug and Rare Pediatric Disease designations from the FDA, Orphan Drug designation from the European Commission and Innovative Licensing and Access Pathway designation from the Medicines and Healthcare products Regulatory Agency.

About Rett Syndrome
Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene encoding methyl CpG-binding protein 2 (MECP2), which is essential for regulating neuronal and synaptic function in the brain. The disorder is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities and shortened life expectancy. Rett syndrome progression is divided into four key stages, beginning with early onset stagnation at 6 to 18 months of age followed by rapid regression, plateau and late motor deterioration. Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability. Currently, there are no approved disease-modifying therapies that treat the genetic root cause of the disease. Rett syndrome caused by a pathogenic/likely pathogenic MECP2 mutation is estimated to affect between 15,000 and 20,000 patients in the U.S., EU, and U.K.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the potential of TSHA-102, including the reproducibility and durability of any favorable results initially seen in our first patients dosed in the REVEAL trials, the potential for TSHA-102 to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and the potential benefits of Regenerative Medicine Advanced Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations for TSHA-102. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (“SEC”) filings, including in our Annual Report on Form 10-K for the full-year ended December 31, 2023, which is available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that we make from time to time with the SEC. Additional information will be made available in other filings that we make from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

Company Contact:
Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com

Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com

FAQ

What is the RMAT designation granted by the FDA for TSHA-102?

The Regenerative Medicine Advanced Therapy (RMAT) designation granted by the FDA to TSHA-102 allows for increased dialogue with the FDA to support expedited development and review of the therapy in clinical evaluation for Rett syndrome.

What clinical trials is TSHA-102 being evaluated in?

TSHA-102 is being evaluated in the REVEAL Phase 1/2 adolescent and adult trial in Canada and the U.S., as well as in the REVEAL Phase 1/2 pediatric trial in the U.S. and cleared in the U.K.

Who granted the RMAT designation to TSHA-102?

The United States Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to TSHA-102 for its potential in treating Rett syndrome.

What does the RMAT designation enable for sponsor companies?

The RMAT designation enables sponsor companies to have increased interactions with the FDA involving senior managers, expediting drug development.

What data led to the RMAT designation for TSHA-102?

The RMAT designation was granted based on the review of safety and efficacy data from the first three patients dosed with TSHA-102 in the REVEAL Phase 1/2 trials involving adolescent/adult and pediatric patients.

Who commented on the RMAT designation for TSHA-102 at Taysha Gene Therapies?

Sukumar Nagendran, M.D., President and Head of R&D of Taysha, commented on the RMAT designation, highlighting the therapy's potential to bring meaningful change to patients and families living with Rett syndrome.